- Home
- CIEN vs BIIB Comparison
CIEN vs BIIB Comparison
Compare CIEN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIEN
- BIIB
- Stock Information
- Founded
- CIEN 1992
- BIIB 1978
- Country
- CIEN United States
- BIIB United States
- Employees
- CIEN N/A
- BIIB N/A
- Industry
- CIEN Telecommunications Equipment
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CIEN Utilities
- BIIB Health Care
- Exchange
- CIEN Nasdaq
- BIIB Nasdaq
- Market Cap
- CIEN 19.5B
- BIIB 18.7B
- IPO Year
- CIEN 1997
- BIIB 1991
- Fundamental
- Price
- CIEN $185.50
- BIIB $148.68
- Analyst Decision
- CIEN Buy
- BIIB Buy
- Analyst Count
- CIEN 14
- BIIB 25
- Target Price
- CIEN $128.31
- BIIB $183.05
- AVG Volume (30 Days)
- CIEN 2.4M
- BIIB 1.6M
- Earning Date
- CIEN 12-11-2025
- BIIB 10-30-2025
- Dividend Yield
- CIEN N/A
- BIIB N/A
- EPS Growth
- CIEN 3.32
- BIIB 31.67
- EPS
- CIEN 0.98
- BIIB 10.45
- Revenue
- CIEN $4,541,635,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- CIEN $19.58
- BIIB $2.03
- Revenue Next Year
- CIEN $16.70
- BIIB N/A
- P/E Ratio
- CIEN $186.85
- BIIB $14.27
- Revenue Growth
- CIEN 12.97
- BIIB 3.36
- 52 Week Low
- CIEN $49.21
- BIIB $110.04
- 52 Week High
- CIEN $186.32
- BIIB $187.28
- Technical
- Relative Strength Index (RSI)
- CIEN 75.90
- BIIB 55.64
- Support Level
- CIEN $173.80
- BIIB $148.10
- Resistance Level
- CIEN $186.32
- BIIB $151.91
- Average True Range (ATR)
- CIEN 7.56
- BIIB 3.29
- MACD
- CIEN 0.04
- BIIB -0.08
- Stochastic Oscillator
- CIEN 97.52
- BIIB 68.36
About CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.